Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) is expected to be releasing its earnings data on Thursday, March 20th. Analysts expect Avalo Therapeutics to post earnings of ($1.29) per share for the quarter.
Avalo Therapeutics Trading Down 6.8 %
Shares of AVTX stock traded down $0.56 on Friday, hitting $7.66. The company had a trading volume of 33,867 shares, compared to its average volume of 211,142. The stock's 50-day moving average is $7.45 and its two-hundred day moving average is $9.12. Avalo Therapeutics has a twelve month low of $4.60 and a twelve month high of $34.46.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on AVTX. Piper Sandler began coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an "overweight" rating and a $48.00 price target for the company. Wedbush reissued an "outperform" rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research note on Thursday. HC Wainwright reissued a "neutral" rating on shares of Avalo Therapeutics in a research note on Thursday. Finally, BTIG Research initiated coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They set a "buy" rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Avalo Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $35.33.
View Our Latest Report on AVTX
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Further Reading
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
